drugset / Trial / NCT03278925

Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis

NCT03278925

Phase 1 Active not recruiting 14 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This phase I trial studies the side effects and best dose of defined green tea catechin extract and to see how well it works in preventing liver cancer in participants with cirrhosis. Higher levels of the molecule gamma-OHPdG may be found in participants with cirrhosis, which may mean a higher risk of the development of liver cancer. Defined green tea catechin extract may work better to lower levels of gamma-OHPdG and prevent the development of liver cancer.

Timeline

Start
2018-08-09
Primary completion
2023-06-16
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Epigallocatechin gallate Small molecule Oral

Indications